Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CorMedix (CRMD) EBITDA (2016 - 2025)

CorMedix (CRMD) has disclosed EBITDA for 14 consecutive years, with -$84994.0 as the latest value for Q4 2025.

  • Quarterly EBITDA fell 4375.35% to -$84994.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$88000.0 through Dec 2025, down 2833.33% year-over-year, with the annual reading at -$88000.0 for FY2025, 2833.33% down from the prior year.
  • EBITDA hit -$84994.0 in Q4 2025 for CorMedix, down from $8205.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $8205.0 in Q3 2025 to a low of -$11.3 million in Q2 2023.
  • Historically, EBITDA has averaged -$4.7 million across 5 years, with a median of -$6.8 million in 2022.
  • Biggest YoY gain for EBITDA was 142.11% in 2025; the steepest drop was 4375.35% in 2025.
  • Year by year, EBITDA stood at -$7.8 million in 2021, then fell by 4.78% to -$8.2 million in 2022, then dropped by 19.32% to -$9.8 million in 2023, then soared by 100.02% to $1988.0 in 2024, then crashed by 4375.35% to -$84994.0 in 2025.
  • Business Quant data shows EBITDA for CRMD at -$84994.0 in Q4 2025, $8205.0 in Q3 2025, and -$5121.0 in Q2 2025.